| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
One disadvantage of the conventional human hepatocyte monolayer culture method is that resulting cells exhibit a shorter lifespan and are unable to stably maintain liver-specific functions, including cytochrome P450 (CYP450) activity.
This study thus aimed to develop an ex vivo artificial liver exhibiting sustained CYP450 activity. Canine primary cultured hepatocyte (cHep) or bone marrow stem cell (cBMSC)-derived hepatocyte-like cells (ciHep) were co-cultured with human umbilical vein endothelial cells (HUVECs) and adipose tissue-derived mesenchymal stem cells (AD-MSCs) to generate φ500μm spheroids. Relative to spheroids containing ciHep, those containing cHep maintained a higher day-three level of CYP450 gene expression. Spheroids were inserted into the “Kenzan” using a 3D bio-printer (Rejenova®) and cultured in a perfusion chamber for seven days to prepare artficial liver structures. Histologically, hepatocytes were MSC-coated.
|
